# Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

> **NCT02609776** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 751 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Amivantamab
- **DRUG:** Amivantamab
- **DRUG:** Lazertinib
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02609776
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 751 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609776, "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT02609776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*